首页>投融资
Krystal Biotech
上市后再融资
Krystal Biotech, Inc.是一家致力于为患有皮肤病的患者开发和商业化新型治疗的基因治疗公司。该公司开发了一种专有的基因治疗平台,它们称为皮肤TARgeted Delivery平台或STAR-D平台,其由基于单纯疱疹病毒1或HSV-1的正在申请专利的工程病毒载体和皮肤优化的基因转移技术,开发了现成的皮肤病治疗方案。他们最初使用STAR-D平台开发由单一基因缺失或突变引起的罕见或孤儿皮肤病学适应症治疗,并计划利用该平台扩大其未来的其他皮肤病学指征。该公司相信他们是第一家寻求使用基因治疗开发可用于皮肤病学指征的产品的生物技术公司,而不需要单独定制的治疗,它们被称为“现成”治疗。他们认为,他们的组织和技术将受益于一系列优势,使他们能够在开发基因治疗皮肤病学指征的基础上创造和建立领导地位。
基本信息
-
公司全称Krystal Biotech Inc
-
类型基因治疗疗法研发商
-
产业领域药品研发/制造、生物药
-
公司人数101~500人
-
地址2100 Wharton Street Suite 701 Pittsburgh Pennsylvania 15203
-
联系电话1-412-5865830
-
邮箱inquiries@krystalbio.com
-
成立时间2015-01-01
投融资
-
2023-05-22上市后再融资1.6亿美元Avoro Capital AdvisorsRedmile GroupBraidwellFrazier Management
-
2021-12-01增发未透露未透露
-
2018-10-23增发6900万美元未透露
-
2018-08-16上市后再融资1000万美元未透露
-
2017-09-20上市3682.8万美元未透露
-
2017-08-08股权融资700万美元Sun Pharmaceutical
- 加载更多
相关投融资企业
捐赠/众筹/授予
igaTx 是一家生物技术公司,开发工程化单体 IgA 中性粒细胞接合器,以释放中性粒细胞对癌症的肿瘤杀伤能力,以及针对传染病的工程化二聚体 IgA 杀伤能力。该公司在工程治疗性 IgA 方面的前沿方法基于 Jeanette Leusen 教授在乌得勒支医学中心(荷兰乌得勒支)进行的开创性工作,并广泛适用于许多不同疾病。
C轮
SiteOne Therapeutics, founded by Stanford University, is a biotechnology company focused on the development of long-acting analgesics, non-norcotic analgecis and diagnostic imaging agents for pain and cancer.In May 2023, SiteOne Therapeutics Inc received a grant for up to $15 million from the National Institute on Drug Abuse.In January 2017, the company raised $15 million in a series B round of financing
A轮
PsiOxus Therapeutics Ltd was formed from the merger of Myotec Therapeutics and Hybrid BioSystems in December 2010. The company is focused on the development of novel therapeutics that address cancer and other clinically unmet diseases.Myotec Therapeutics was a spin-out from Imperial Innovations and was set up to develop technology originated at Imperial College London. It focused on repurposing drugs for the treatment of cachexia, with the intention of out-licensing after completion of phase II studies.In June 2017, the company expanded its operations into a 21,000 sq ft state-of-the-art facility on the Abingdon Science Park in Oxfordshire, UK and a new US facility in Plymouth Meeting near Philadelphia, PA.In April 2012, PsiOxus announced that it would expand into new facilities at the Milton Park in Oxfordshire, UK. The expansion would include a bespoke laboratory for the research and development of novel viral therapeutics; later that month, the facility was opened.By Decem